MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, selling common stock and pre-funded warrants to institutional investors. The funds will support general corporate purposes, including a $45 million payment linked to the recent FDA approval of their drug Furoscix ReadyFlow™, an autoinjector for treating edema in heart failure and chronic kidney disease. The financing is expected to close around July 24, 2026, and MannKind plans to register the resale of these securities with the SEC. This capital raise aims to strengthen MannKind's position as it advances treatments for cardiometabolic and orphan lung diseases.
Tesla introduced the Cybercab on September 4, 2026, just six weeks after announcing it would not pursue volume production of the vehicle this year. This launch signals Tesla's continued interest in the Cybercab despite scaling back mass production pl...
Florida Athletics has signed a multiyear sponsorship deal with Ripple, placing the XRP logo on the field at Ben Hill Griffin Stadium starting with the 2026 football season. The agreement, reportedly worth $5 million annually, also includes digital an...
August jobs growth in the US beat expectations with a gain of 217,000, including upward revisions for June and July. This strong employment data reflects ongoing economic expansion with rising manufacturing, construction, and wage income outpacing in...
Dash surged 42.68% to $67.04, leading gains among cryptocurrencies due to renewed investor interest in privacy-focused coins, despite no specific event triggering the rise. Meanwhile, Cardano fell 5.49% amid market adjustments following recent upgrad...
Kahn Swick & Foti, a law firm led by former Louisiana Attorney General Charles C. Foti, Jr., has started an investigation into Freeport-McMoRan following a fatal mud rush incident at its Grasberg mine in Indonesia. The incident, which resulted in two...
